The OnyCOE-t™ questionnaire: Responsiveness and clinical meaningfulness of a patient-reported outcomes questionnaire for toenail onychomycosis

Health and Quality of Life Outcomes

Volumn 4, Issue , 2006, Pages

  Potter, Lori P ^a   Mathias, Susan D ^a   Raut, Monika ^b   Kianifard, Farid ^c   Tavakkol, Amir ^c  

^a Ovation Research Group   (United States)

^b Ortho Biotech Products LP   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

TERBINAFINE; ANTIFUNGAL AGENT; NAPHTHALENE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTRUCT VALIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEBRIDEMENT; DOSE RESPONSE; ESTHETICS; FEMALE; FREQUENCY ANALYSIS; HUMAN; INTERNAL CONSISTENCY; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; MULTICENTER STUDY; ONYCOE T; OUTCOMES RESEARCH; PATIENT SATISFACTION; PHYSICAL ACTIVITY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELIABILITY; SCORING SYSTEM; SYMPTOMATOLOGY; TOENAIL ONYCHOMYCOSIS; ADOLESCENT; DRUG EFFECT; INSTRUMENTATION; MIDDLE AGED; NAIL; ONYCHOMYCOSIS; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; PSYCHOMETRY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SICKNESS IMPACT PROFILE; SKIN DISEASE; TREATMENT OUTCOME; VALIDATION STUDY;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; DEBRIDEMENT; FEMALE; FOOT DERMATOSES; HUMANS; MALE; MIDDLE AGED; NAILS; NAPHTHALENES; ONYCHOMYCOSIS; PATIENT SATISFACTION; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SICKNESS IMPACT PROFILE; TREATMENT OUTCOME;

EID: 33748972317     PISSN: 14777525     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-4-50     Document Type: Article

References (12)

1. Elewski BE: The effect of toenail onychomycosis on patient quality of life. Int J Dermatol 1997, 36(10):754-756.
2. Scher RK: Onychomycosis is more than a cosmetic problem. Br J Dermatol 1994, 130 Suppl 43:15.
3. Lubeck DP, Patrick DL, McNulty P, Fifer SK, Birnbaum J: Quality of life of persons with onychomycosis. Qual Life Res 1993, 2(5):341-348.
4. Lubeck DP, Gause D, Schein JR, Prebil LE, Potter LP: A health-related quality of life measure for use in patients with onychomycosis: a validation study. Qual Life Res 1999, 8(1-2):121-129.
5. Drake LA, Patrick DL, Fleckman P, Andr J, Baran R, Haneke E, Sapede C, Tosti A: The impact of onychomycosis on quality of life: development of an international onychomycosis-specific questionnaire to measure patient quality of life. J Am Acad Dermatol 1999, 41(2 Pt 1):189-196.
6. Drake LA, Scher RK, Smith EB, Faich GA, Smith SL, Hong JJ, Stiller MJ: Effect of onychomycosis on quality of life. J Am Acad Dermatol 1998, 38(5 Pt 1):702-704.
7. Pasta DJ, Potter LP: Exploratory Variable Clustering for Integrating Analyses: San Francisco, CA.; 1996:297-301.
8. Cronbach LJ: Coefficient alpha and the internal structure of tests. Volume 16. Psychometrika; 1951:297-334.
9. Guyatt GH, Bombardier C, Tugwell PX: Measuring disease-specific quality of life in clinical trials. Cmaj 1986, 134(8):889-895.
10. Guyatt G, Walter S, Norman G: Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis 1987, 40(2):171-178.
11. Potter LP, Mathias SD: The OnyCOE-t Questionnaire: Reliability and Validity of a Patient Reported Outcomes Questionnaire: October 19-22; San Francisco, CA.; 2005.
12. Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res 2002, 11(3):193-205.